Literature DB >> 30042221

Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens.

Darren M Roberts1,2,3, Jacob Sevastos4,5, Jane E Carland6,5, Sophie L Stocker6,5, Tom N Lea-Henry2,7.   

Abstract

A change in pharmacokinetics can alter drug exposure and predispose the patient to either over- or underdosing, potentially resulting in adverse drug reactions or therapeutic failure. Kidney disease is characterized by multiple physiologic effects, which induce clinically significant changes in pharmacokinetics. These vary between individuals and may be quantitated in certain instances. An understanding of pharmacokinetic concepts is, therefore, important for a rational approach to the design of drug dosing regimens for the delivery of personalized medical care. Whether kidney disease is acute or chronic, drug clearance decreases and the volume of distribution may remain unchanged or increase. AKI is defined by dynamic changes in kidney function, which complicates attempts to accurately quantify drug clearance. In contrast, changes in drug clearance progress more slowly with CKD. In general, kidney replacement therapies increase drug clearance, but the extent to which this occurs depends on the modality used and its duration, the drug's properties, and the timing of drug administration. However, the changes in drug handling associated with kidney disease are not isolated to reduced kidney clearance and an appreciation of the scale of potential derangements is important. In most instances, the first dose administered in patients with kidney disease is the same as in patients with normal kidney function. However, in some cases, a higher (loading) initial dose is given to rapidly achieve therapeutic concentrations, followed by a lower maintenance dose, as is well described when prescribing anti-infectives to patients with sepsis and AKI. This review provides an overview of how pharmacokinetic principles can be applied to patients with kidney disease to personalize dosage regimens. Patients with kidney disease are a vulnerable population and the increasing prevalence of kidney disease means that these considerations are important for all prescribers.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Acute Kidney Injury; Drug-Related Side Effects and Adverse Reactions; Pharmacokinetics; Prevalence; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sepsis; Vulnerable Populations; acute kidney injury; chronic kidney disease; clearance; dialysis; kidney disease; personalized medicine; volume of distribution

Year:  2018        PMID: 30042221      PMCID: PMC6086693          DOI: 10.2215/CJN.05150418

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  45 in total

1.  Peritoneal dialysis-related infections recommendations: 2010 update.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Judith Bernardini; Ana E Figueiredo; Amit Gupta; David W Johnson; Ed J Kuijper; Wai-Choong Lye; William Salzer; Franz Schaefer; Dirk G Struijk
Journal:  Perit Dial Int       Date:  2010 Jul-Aug       Impact factor: 1.756

Review 2.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

Review 3.  Principles and operational parameters to optimize poison removal with extracorporeal treatments.

Authors:  Josée Bouchard; Darren M Roberts; Louise Roy; Georges Ouellet; Brian S Decker; Bruce A Mueller; Simon Desmeules; Marc Ghannoum
Journal:  Semin Dial       Date:  2014-05-14       Impact factor: 3.455

Review 4.  Medication management on sick days.

Authors:  Tom N Lea-Henry; Jonathan Baird-Gunning; Elizabeth Petzel; Darren M Roberts
Journal:  Aust Prescr       Date:  2017-10-03

5.  In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae.

Authors:  G G Zhanel; M Walters; N Laing; D J Hoban
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

Review 6.  Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.

Authors:  Brian Wispelwey
Journal:  Clin Infect Dis       Date:  2005-07-15       Impact factor: 9.079

7.  Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen.

Authors:  Roger Jelliffe
Journal:  Am J Nephrol       Date:  2002 Jul-Aug       Impact factor: 3.754

8.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

9.  Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis.

Authors:  Darren M Roberts; Dwarakanathan Ranganathan; Steven C Wallis; Julie M Varghese; Adrian Kark; Jeffrey Lipman; Jason A Roberts
Journal:  Perit Dial Int       Date:  2016-01-13       Impact factor: 1.756

10.  Creatinine kinetics and the definition of acute kidney injury.

Authors:  Sushrut S Waikar; Joseph V Bonventre
Journal:  J Am Soc Nephrol       Date:  2009-02-25       Impact factor: 10.121

View more
  11 in total

1.  Adverse Drug Effects in Patients with CKD: Primum Non Nocere.

Authors:  Mark A Perazella; Thomas D Nolin
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-01       Impact factor: 8.237

Review 2.  Clinical Pharmacology of Antibiotics.

Authors:  Rachel F Eyler; Kristina Shvets
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-12       Impact factor: 8.237

3.  Drug-Related Problems in Hospitalised Patients with Chronic Kidney Disease: A Systematic Review.

Authors:  Wadia S Alruqayb; Malcolm J Price; Vibhu Paudyal; Anthony R Cox
Journal:  Drug Saf       Date:  2021-09-12       Impact factor: 5.606

4.  Population Pharmacokinetic Modelling for Nifedipine to Evaluate the Effect of Parathyroid Hormone on CYP3A in Patients with Chronic Kidney Disease.

Authors:  Chengxiao Fu; Qi Pei; Wu Liang; Bo Yang; Wei Li; Jun Liu; Hongyi Tan; Chengxian Guo; Hao Zhang; Guoping Yang
Journal:  Drug Des Devel Ther       Date:  2022-07-13       Impact factor: 4.319

Review 5.  How to adjust drug doses in chronic kidney disease.

Authors:  Maurizio Stefani; Richard F Singer; Darren M Roberts
Journal:  Aust Prescr       Date:  2019-10-01

6.  The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine.

Authors:  Kazuya Fukumura; Tadaaki Yamada; Takaaki Yokota; Akira Kawasaki
Journal:  Clin Pharmacol Drug Dev       Date:  2019-04-12

7.  Impact of Adverse Drug Reactions in Patients with End Stage Renal Disease in Greece.

Authors:  Marios Spanakis; Marianna Roubedaki; Ioannis Tzanakis; Michail Zografakis-Sfakianakis; Evridiki Patelarou; Athina Patelarou
Journal:  Int J Environ Res Public Health       Date:  2020-12-06       Impact factor: 3.390

Review 8.  Drug-Dosing Adjustment in Dogs and Cats with Chronic Kidney Disease.

Authors:  Francesca De Santis; Andrea Boari; Francesco Dondi; Paolo Emidio Crisi
Journal:  Animals (Basel)       Date:  2022-01-21       Impact factor: 2.752

9.  Pharmacist-led Medication Counseling for Patients Undergoing Hemodialysis: A Path to Better Adherence.

Authors:  Lolwa Al-Abdelmuhsin; Maha Al-Ammari; Salmeen D Babelghaith; Syed Wajid; Yousef A Asiri; Mansour S Almetawaz; Sultan M Alghadeer; Mohamed N Al-Arifi
Journal:  Int J Environ Res Public Health       Date:  2020-04-01       Impact factor: 3.390

Review 10.  Pharmacokinetics in children with chronic kidney disease.

Authors:  Anne M Schijvens; Saskia N de Wildt; Michiel F Schreuder
Journal:  Pediatr Nephrol       Date:  2019-08-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.